HeartSciences™ MyoVista® high sensitivity ECG (hsECG™) Cardiac Testing Device is a breakthrough in the early detection of cardiac dysfunction*. It is designed to fill a diagnostic gap identifying both asymptomatic and symptomatic patients at elevated cardiac risk of an adverse event. MyoVista hsECG device address a major clinical, technical and economic need in testing of cardiac dysfunction with an easy to adopt, easy to interpret, low cost and non-invasive solution that does not require any change in traditional 12-lead resting ECG clinical workflow.
MyoVista hsECG device produces a sensitivity of 78% and a specificity of 71%* for the detection of diastolic dysfunction. During a recent clinical trial MyoVista technology produced a sensitivity of 88% and a specificity of 87%* using machine learning analysis and indicates even greater future capability for the detection of diastolic dysfunction.
• Data on file at HeartSciences